ST. GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News: Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, i…
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
ST. GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News: Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, i…